We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ModiQuest Announces Publication of Novel Antibodies
News

ModiQuest Announces Publication of Novel Antibodies

ModiQuest Announces Publication of Novel Antibodies
News

ModiQuest Announces Publication of Novel Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ModiQuest Announces Publication of Novel Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In this publication, ModiQuest describes the discovery of novel therapeutic anti-citrullinated protein antibodies (tACPAs) that prevent the onset and/or exacerbation of inflammation and that prevent or strongly reduce the occurrence of swelling and joint damage, using a collagen antibody-induced arthritis mouse model. The ACPAs discovered by ModiQuest are directed against a citrullinated epitope in histone-2A protein in man and mouse.
 
ModiQuest has made this discovery using its proprietary antibody discovery technology platforms M-Fuse™ (highly efficient hybridoma electrofusion technology), M-Select™ (B-cell selection technology for low immunogenic or multiple antigen targets) and M-Phage™ (proprietary phase display libraries). All three technology platforms are also used by ModiQuest’s service business, ModiQuest Research BV, for custom antibody lead generation in third party service projects.
 
“The novel tACPA leads we have discovered offer a new way to contribute to the treatment of rheumatoid arthritis, and we are today in discussions with a number of pharmaceutical companies to progress the tACPA leads into clinical development”, says Dr. Jos Raats, CEO of ModiQuest. “The discovery of these antibody leads again demonstrates the huge potential of our M-Fuse™, M-Select™ and M-Phage™ technologies for the discovery of novel therapeutic and diagnostic antibodies against low-immunogenic targets.”

Advertisement